Patients with an autoimmune disorder called antineutrophil cytoplasmic antibody–associated vasculitis produce antibodies that damage blood vessels in the body.
Patients with an autoimmune disorder called antineutrophil cytoplasmic antibody–associated vasculitis produce antibodies that damage blood vessels in the body. In some cases, patients’ antibodies target a protein called myeloperoxidase. New research published in Arthritis & Rheumatology indicates that for patients in remission, reappearance of antibodies against myeloperoxidase is a sign that patients will experience a relapse of their disease.
The findings suggest that patients should undergo routine monitoring of antibodies against myeloperoxidase.
“Our results could be helpful in daily clinical practice related to antineutrophil cytoplasmic antibody–associated vasculitis,” said co-author Dr. Ken-Ei Sada, of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/art.40538
About Journal
Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists and clinicians interested in the natural history, pathophysiology, treatment, and outcome of the rheumatic diseases. Arthritis & Rheumatology publishes the highest quality basic and clinical research related to the rheumatic diseases, encompassing a wide range of areas of investigative activity. In addition, the journal publishes review articles, editorials, and other educational material intended for both researchers and clinicians. Serving the worldwide community of rheumatology investigators and clinicians, Arthritis & Rheumatology is known internationally as a top rheumatology research journal.
The American College of Rheumatology ( www.rheumatology.org ) is the leading professional organization dedicated to the study, prevention, and treatment of debilitating disorders of the joints, muscles, and bones.
Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com